Navigation Links
Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
Date:9/24/2009

ct marketing expense.

Operating income totaled approximately $9.7 million, a 28.4% increase from the $7.6 million reported for fiscal year 2008. Operating margins were 22.7% and 22.6% for the fiscal year 2009 and 2008, respectively.

For fiscal 2009, net income was approximately $7.9 million, a 32.4% increase from $6.0 million recorded for fiscal 2008 and surpassed previously announced guidance by approximately 5.3%. Diluted earnings per share were $0.32, compared to $0.31 in the same period 2008, based on 24.8 million and 19.1 million shares for 2009 and 2008, respectively. The increase in the diluted shares was related to preferred stock which carries a fixed conversion price of $1.60.

The provision for income taxes was $1.6 million and $1.2 million for fiscal 2009 and 2008 with an effective tax rate was 17.2% and 17.1%, respectively.

"China's healthcare reform is being implemented to provide basic medical care for its 1.3 billion citizens by 2020 with approximately $126 billion being allocated during the next three years alone. This initiative is well underway as evidenced by the build-out of new Clinics and the publishing of the formal EDL. This creates significant growth opportunities for Chinese pharmaceutical companies like Tianyin which possess a diversified product portfolio and extensive sales and distribution channels. We currently have 17 products in our R&D pipeline which address wide range of chronic and critical conditions. We expect to receive additional SFDA approvals during fiscal 2010 which will further diversify our branded product base with high margin revenue potential while enabling us to further differentiate our company from our competitors. We will leverage the new production capacity to continue the growth momentum in fiscal 2010 and beyond," concluded Dr. Jiang.

Balance Sheet and Cash Flow

The Company had a current ratio
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
5. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
6. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
7. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
8. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
9. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
10. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... NY (PRWEB) May 23, 2013 ... GRAPHALLOY® self-lubricating bushings mounted in stainless steel ... self-lubricating properties of GRAPHALLOY with the application and ... Stainless Steel Pillow Blocks work exceptionally well ... corrosive or hostile liquids such as acids, alkalies, ...
(Date:5/23/2013)... 23, 2013  Rahal Letterman Lanigan Racing (RLL) and ... stem cell banking and therapeutics, announced today that StemCyte ... Acorn Stairlifts Indy car driven by James ... the IZOD IndyCar 2013 season.   StemCyte, ... support awareness of umbilical cord blood banking and its ...
(Date:5/23/2013)... 23, 2013 VG Energy, an agricultural ... DAK Renewable Research to conduct field trials using ... Energy is a majority owned subsidiary of VG ... VG Energy,s exclusively licensed compound LipidMax selectively inhibits ... in plants, possessing a wide variety of applications ...
(Date:5/23/2013)... , May 23, 2013 BioTrends Research ... advisory firms for specialized biopharmaceutical issues, finds that, ... infectious disease specialists reported that in the past ... intentionally delaying treatment) in anticipation of the next ... months ago, when only 6 percent reported that ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... Exchange Symbol: MS, EDMONTON, Nov. 12 /PRNewswire-FirstCall/ ... in the treatment of multiple sclerosis (MS), today,announced ... in its MAESTRO-03,U.S. pivotal phase III clinical trial ... sclerosis (SPMS). An interim safety and,efficacy analysis will ...
... GROVE, Ill., Nov. 12 Alma Lasers Ltd., ... innovative aesthetic,laser, light-based, and radiofrequency systems, today announced ... company in the Deloitte Technology,Fast 50 program. The ... based on the percentage revenue growth over five ...
... Chronic Pain Conditions in Patients Who are Already ... ... Pa., Nov. 12 Cephalon, Inc. (Nasdaq:,CEPH) today announced it has ... Drug Administration (FDA) seeking approval to,market FENTORA(R) (fentanyl buccal tablet) [C-II] ...
Cached Biology Technology:BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 2BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 3Alma Lasers Ranked 9th in Deloitte Technology Fast 50 Award 2Cephalon Submits Supplemental New Drug Application for FENTORA 2Cephalon Submits Supplemental New Drug Application for FENTORA 3Cephalon Submits Supplemental New Drug Application for FENTORA 4Cephalon Submits Supplemental New Drug Application for FENTORA 5Cephalon Submits Supplemental New Drug Application for FENTORA 6Cephalon Submits Supplemental New Drug Application for FENTORA 7
(Date:5/22/2013)... NEW YORK CITY, May 22, 2013 U.S. Forest ... multi-disciplinary team that, with funding from the TKF Foundation, ... spaces help communities and individuals recover from tragedy. , ... is one of six projects selected for grant funding. ... spaces and sacred spaces in recovery and resiliency, the ...
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
(Date:5/22/2013)... new, streamlined approach to genetic engineering drastically reduces ... genes into bacteria, the workhorses of biotechnology, scientists ... Synthetic Biology , the method paves the way ... drug development, environmental cleanup and other activities. , ... integrating, a piece of the genetic material DNA ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... is available in Spanish . Research published ... significant step in knowing the causes of cancer better, especially breast ... the cells known as SIRT3, induces the proliferation of this disease ... target in the development of effective therapies for cancer. The research ...
... parent with young children knows that couples need to work ... and at home. But it may come as a surprise ... work-family balance. According to new research led by biologists at ... fireflies get less support from their mates than females who ...
... SCOTTS VALLEY, Calif., April 5, 2011 Ennova Direct, ... a patent portfolio for sale that is ... USB Flash Drive Devices, MP3 Players (wired and Wireless ... intellectual property includes 6 issued US patents ...
Cached Biology News:Discovery of protein that alters nutrition of breast cancer cells 2Discovery of protein that alters nutrition of breast cancer cells 3In fireflies, flightless females lose out on gifts from males 2In fireflies, flightless females lose out on gifts from males 3Ennova Direct Announces the Sale of its Consumer Electronics/Computer Peripheral Patent Portfolio 2
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
Biology Products: